[{"id":"bad33fae-f9c7-474e-879f-6eabe449864a","acronym":"","url":"https://clinicaltrials.gov/study/NCT02038673","created_at":"2021-01-18T09:21:26.925Z","updated_at":"2024-07-02T16:37:05.880Z","phase":"Phase 1","brief_title":"An Open-label Phase I Study of Orally Available Novel Small-molecule Fibroblast Growth Factor Receptors (FGFR) 1,2,3 and 4 Inhibitor, ASP5878 at Single and Multiple Doses in Patients With Solid Tumors","source_id_and_acronym":"NCT02038673","lead_sponsor":"Astellas Pharma Inc","biomarkers":" FGF19 • FGF23","pipe":"","alterations":" ","tags":["FGF19 • FGF23"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ASP5878"],"overall_status":"Completed","enrollment":" Enrollment 86","initiation":"Initiation: 11/05/2013","start_date":" 11/05/2013","primary_txt":" Primary completion: 07/19/2017","primary_completion_date":" 07/19/2017","study_txt":" Completion: 07/19/2017","study_completion_date":" 07/19/2017","last_update_posted":"2018-10-22"}]